 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Regeneron Pharmaceuticals (REGN) discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally.
The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children.
Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The companys earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers.
Shares have formed a bullish "flag" and higher prices are expected for this stock.
52-Week Trading Range: $107.31 - $220.43
Entry Point: $216.00
Stop Loss: $205.20
Target Price: $237.60
Shares of Regeneron (REGN) are now higher by 14%, or $29.52, to $244.98 after Allergan (AGN) said its treatment for age-related macular degeneration will not move directly into Phase 3 trials. Regeneron's drug Eylea is a treatment for age-related macular degeneration.
Stock has exceeded our target price but we are keeping the position open due to the news. Our previous target was $237.60. We are now raising our target to $260.
REGN has been a great trade for us. We closed the position today at $265. If you elect to stay, adjust your stop loss to $260 to protect your gains.
